Hans Lennernäs
Gründer bei Canthera AB
Profil
Hans Lennernäs is the founder of LIDDS AB, which was founded in 2003.
He is also the founder of DuoCort Pharma AB, Empros Pharma AB, Canthera AB.
Currently, he holds the position of Director at Recipharm Pharmaceutical Development AB and Dr. Lennernäs Biomedical AB.
In the past, he worked as an Independent Director at Nanologica AB and as a Professor at the University of Uppsala.
He obtained his doctorate degree from the University of Uppsala.
Aktive Positionen von Hans Lennernäs
Unternehmen | Position | Beginn |
---|---|---|
Recipharm Pharmaceutical Development AB | Direktor/Vorstandsmitglied | - |
Hans Lennernäs Biomedical AB
Hans Lennernäs Biomedical AB Miscellaneous Commercial ServicesCommercial Services Hans Lennernäs Biomedical AB is a private company based in Uppsala, Sweden. The Swedish company provides medical research, development, and teaching services. Additionally, they own and manage real estate. | Direktor/Vorstandsmitglied | - |
Canthera AB
Canthera AB Pharmaceuticals: MajorHealth Technology Canthera AB is a Swedish company that develops, manufactures, and wholesales pharmaceuticals and medical equipment. The private company is based in Uddevalla, Sweden. The company was founded by Hans Lennernäs. | Gründer | - |
Ehemalige bekannte Positionen von Hans Lennernäs
Unternehmen | Position | Ende |
---|---|---|
University of Uppsala | Corporate Officer/Principal | - |
DuoCort Pharma AB
DuoCort Pharma AB Pharmaceuticals: MajorHealth Technology DuoCort Pharma AB conducts research, development, training, marketing, and sales in the medical field. The firm operates drug development company focused on improving glucocorticoid therapy. It develops Plenadren, a once daily dual-release hydrocortisone replacement therapy for patients with chronic adrenal insufficiency. The company was founded on July 6, 2007 and is headquartered in Stockholm, Sweden. | Gründer | - |
Empros Pharma AB
Empros Pharma AB Pharmaceuticals: MajorHealth Technology Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest. | Gründer | - |
NANOLOGICA AB | Direktor/Vorstandsmitglied | - |
LIDDS AB | Gründer | - |
Ausbildung von Hans Lennernäs
University of Uppsala | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
LIDDS AB | Health Technology |
NANOLOGICA AB | Health Technology |
Private Unternehmen | 5 |
---|---|
DuoCort Pharma AB
DuoCort Pharma AB Pharmaceuticals: MajorHealth Technology DuoCort Pharma AB conducts research, development, training, marketing, and sales in the medical field. The firm operates drug development company focused on improving glucocorticoid therapy. It develops Plenadren, a once daily dual-release hydrocortisone replacement therapy for patients with chronic adrenal insufficiency. The company was founded on July 6, 2007 and is headquartered in Stockholm, Sweden. | Health Technology |
Recipharm Pharmaceutical Development AB | Health Technology |
Empros Pharma AB
Empros Pharma AB Pharmaceuticals: MajorHealth Technology Empros Pharma AB is a pharmaceutical company based in Sweden that focuses on developing drugs to combat obesity. The CEO is Arvid Söderhäll, and the company is located in Solna, Sweden. The Swedish company has developed a weight-loss combination product containing orlistat and acarbose, which has been tested in a randomized, placebo-controlled trial. Empros Pharma's main drug, EMP16, is designed to delay food digestion and absorption processes in the small intestine using a proprietary advanced drug delivery technology. The company was founded in 2013 by senior researchers and entrepreneurs at Uppsala University, along with external investor Flerie Invest. | Health Technology |
Hans Lennernäs Biomedical AB
Hans Lennernäs Biomedical AB Miscellaneous Commercial ServicesCommercial Services Hans Lennernäs Biomedical AB is a private company based in Uppsala, Sweden. The Swedish company provides medical research, development, and teaching services. Additionally, they own and manage real estate. | Commercial Services |
Canthera AB
Canthera AB Pharmaceuticals: MajorHealth Technology Canthera AB is a Swedish company that develops, manufactures, and wholesales pharmaceuticals and medical equipment. The private company is based in Uddevalla, Sweden. The company was founded by Hans Lennernäs. | Health Technology |